Valeurs | |||||
Le rangement donne un aperçu de toutes les valeurs mobilières classées de manière alphabétique ou selon les indices. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Nom | Code | Analysis date | Cours de clôture | +/- % |
Accenture A | ACN | 5. nov 2024 | 345.49 | +0.46 |
Acco Brands | ACCO | 5. nov 2024 | 5.81 | +4.50 |
Accolade | ACCD | 5. nov 2024 | 3.21 | +1.90 |
Accuray | ARAY | 5. nov 2024 | 1.92 | +6.67 |
Acelyrin | SLRN | 5. nov 2024 | 6.00 | +3.09 |
Achieve Life Sciences | ACHV | 5. nov 2024 | 4.85 | +2.32 |
Achilles Therapeutics ADR | ACHL | 5. nov 2024 | 1.03 | +0.98 |
ACI Worldwide | ACIW | 5. nov 2024 | 51.17 | +2.03 |
Aclarion | ACON | 5. nov 2024 | 0.18 | -0.11 |
Aclaris Therapeutics | ACRS | 5. nov 2024 | 2.22 | +2.30 |
ACM Research A | ACMR | 5. nov 2024 | 18.18 | -2.05 |
Acme United | ACU | 5. nov 2024 | 40.06 | +3.06 |
ACNB | ACNB | 5. nov 2024 | 43.18 | +3.33 |
ACRES Commercial Realty | ACR | 5. nov 2024 | 15.58 | -0.89 |
ACRES Commercial Realty C Pref | ACR-C | 5. nov 2024 | 24.91 | +0.04 |
ACRES Commercial Realty D Pref | ACR-D | 5. nov 2024 | 23.24 | +1.48 |
Acrivon Therapeutics | ACRV | 5. nov 2024 | 7.83 | -0.25 |
Actelis Networks | ASNS | 5. nov 2024 | 1.33 | -1.48 |
Actinium Pharmaceuticals | ATNM | 5. nov 2024 | 1.88 | +6.82 |
Active Bear ETF | HDGE | 5. nov 2024 | 18.23 | -1.56 |
Active U.S. Real Estate Powershares | PSR | 5. nov 2024 | 96.24 | +1.04 |
Actuate Therapeutics | ACTU | 5. nov 2024 | 8.80 | 0.00 |
Acuity Brands | AYI | 5. nov 2024 | 314.34 | +2.39 |
Acumen Pharmaceuticals | ABOS | 5. nov 2024 | 3.00 | +1.69 |
Acurx Pharmaceuticals | ACXP | 5. nov 2024 | 1.85 | 0.00 |
Acushnet | GOLF | 5. nov 2024 | 63.24 | +0.91 |
ACV Auctions A | ACVA | 5. nov 2024 | 17.71 | +2.67 |
ACWI Ex-US Index MSCI Ishares | ACWX | 5. nov 2024 | 55.43 | +1.09 |
ACWI Index MSCI Ishares | ACWI | 5. nov 2024 | 118.85 | +1.17 |
Adagene ADR | ADAG | 5. nov 2024 | 3.10 | +1.64 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.